Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TST005 |
Synonyms | |
Therapy Description |
TST005 is a bifunctional fusion protein that consists of the TGF-betaRII extracellular domain linked to an antibody targeting PD-L1, which potentially enhances immune activation and inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 6013). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TST005 | TST-005|TST 005 | TST005 is a bifunctional fusion protein that consists of the TGF-betaRII extracellular domain linked to an antibody targeting PD-L1, which potentially enhances immune activation and inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 6013). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04958434 | Phase I | TST005 | Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |